Impact of the clinical frailty scale on mid-term mortality in patients with ST-elevated myocardial infarction.
Coronary heart disease
Frail
Prognosis
ST-elevated myocardial infarction
Journal
International journal of cardiology. Heart & vasculature
ISSN: 2352-9067
Titre abrégé: Int J Cardiol Heart Vasc
Pays: Ireland
ID NLM: 101649525
Informations de publication
Date de publication:
Mar 2019
Mar 2019
Historique:
received:
31
12
2018
revised:
19
02
2019
accepted:
27
02
2019
entrez:
10
4
2019
pubmed:
10
4
2019
medline:
10
4
2019
Statut:
epublish
Résumé
"Frailty" is associated with poor prognosis in ST-elevated myocardial infarction (STEMI). However, there is little data regarding the impact of the Canadian Study of Health and Aging Clinical Frailty Scale (CFS), a simple and semiquantitative tool for assessing frailty, on mid-term mortality in STEMI patients. A total of 354 consecutive STEMI patients (mean age 69.8 ± 12.4 years; male 76.6%) who underwent percutaneous intervention between July 2014 and March 2017 were retrospectively reviewed. The study endpoint was mid-term mortality according to the CFS classification. Furthermore, in order to clarify the impact of CFS upon admission on mid-term mortality, the independent predictors of all-cause death were evaluated. Patients were categorized into three groups (CFS 1-3, n = 281; CFS 4-5, n = 62; and CFS 6-7, n = 11). During the study period (median 474 days), all-cause death was observed in 39 patients. After multivariate Cox regression analysis, higher CFS (adjusted hazard ratio [HR] 2.34, 95% confidence interval [CI] 1.43-3.85, p < 0.001), higher Killip score (adjusted HR 2.46, 95%CI 1.30-5.78, p = 0.002), and lower serum albumin level (adjusted HR 4.29, 95%CI 2.16-8.51, p < 0.001) were significantly associated with an increased risk of all-cause death. In conclusion, severe frailty was associated with mid-term mortality in STEMI patients who underwent PCI.
Sections du résumé
BACKGROUND
BACKGROUND
"Frailty" is associated with poor prognosis in ST-elevated myocardial infarction (STEMI). However, there is little data regarding the impact of the Canadian Study of Health and Aging Clinical Frailty Scale (CFS), a simple and semiquantitative tool for assessing frailty, on mid-term mortality in STEMI patients.
METHODS
METHODS
A total of 354 consecutive STEMI patients (mean age 69.8 ± 12.4 years; male 76.6%) who underwent percutaneous intervention between July 2014 and March 2017 were retrospectively reviewed. The study endpoint was mid-term mortality according to the CFS classification. Furthermore, in order to clarify the impact of CFS upon admission on mid-term mortality, the independent predictors of all-cause death were evaluated.
RESULTS
RESULTS
Patients were categorized into three groups (CFS 1-3, n = 281; CFS 4-5, n = 62; and CFS 6-7, n = 11). During the study period (median 474 days), all-cause death was observed in 39 patients. After multivariate Cox regression analysis, higher CFS (adjusted hazard ratio [HR] 2.34, 95% confidence interval [CI] 1.43-3.85, p < 0.001), higher Killip score (adjusted HR 2.46, 95%CI 1.30-5.78, p = 0.002), and lower serum albumin level (adjusted HR 4.29, 95%CI 2.16-8.51, p < 0.001) were significantly associated with an increased risk of all-cause death.
CONCLUSION
CONCLUSIONS
In conclusion, severe frailty was associated with mid-term mortality in STEMI patients who underwent PCI.
Identifiants
pubmed: 30963094
doi: 10.1016/j.ijcha.2019.02.014
pii: S2352-9067(19)30003-X
pmc: PMC6437299
doi:
Types de publication
Journal Article
Langues
eng
Pagination
192-198Références
Ann Intern Med. 1999 Mar 16;130(6):461-70
pubmed: 10075613
J Gerontol A Biol Sci Med Sci. 2001 Mar;56(3):M146-56
pubmed: 11253156
Arch Intern Med. 2003 Oct 27;163(19):2345-53
pubmed: 14581255
Ann Epidemiol. 2005 Aug;15(7):483-91
pubmed: 16029840
Int J Cardiol. 2006 Jun 16;110(2):153-9
pubmed: 16043245
CMAJ. 2005 Aug 30;173(5):489-95
pubmed: 16129869
Am Heart J. 2008 May;155(5):883-9
pubmed: 18440336
Source Code Biol Med. 2008 Dec 16;3:17
pubmed: 19087314
Clin Biochem Rev. 2009 Nov;30(4):197-200
pubmed: 20011212
Circ Cardiovasc Qual Outcomes. 2011 Sep;4(5):496-502
pubmed: 21878670
Circulation. 2011 Nov 29;124(22):2397-404
pubmed: 22064593
J Am Coll Cardiol. 2012 Oct 9;60(15):1438-54
pubmed: 23036636
J Am Coll Cardiol. 2013 May 14;61(19):1964-72
pubmed: 23500222
J Am Med Dir Assoc. 2013 Jun;14(6):392-7
pubmed: 23764209
Can J Cardiol. 2013 Dec;29(12):1610-5
pubmed: 24183299
J Cardiol. 2015 Sep;66(3):263-8
pubmed: 25547740
Eur Heart J Acute Cardiovasc Care. 2016 Jun;5(3):231-42
pubmed: 25897147
Circ J. 2015;79(9):2009-16
pubmed: 26118344
BMC Geriatr. 2016 Jun 02;16:117
pubmed: 27250650
Circulation. 2017 May 23;135(21):2013-2024
pubmed: 28302751
Clin Cardiol. 2017 Oct;40(10):925-931
pubmed: 28712144
Am J Cardiol. 2017 Nov 1;120(9):1460-1466
pubmed: 28864322
Eur Heart J. 2018 Jan 7;39(2):119-177
pubmed: 28886621
J Am Med Dir Assoc. 2018 Apr;19(4):296-303
pubmed: 29153753
J Physiother Phys Rehabil. 2017;2(2):null
pubmed: 29226282
PLoS One. 2017 Dec 29;12(12):e0190071
pubmed: 29287123
Cardiovasc Interv Ther. 2018 Apr;33(2):178-203
pubmed: 29594964